VM:CC - Voyageur Pharmaceuticals Announces Appointment of Ethan Mohan as Executive Vice President

(TheNewswire)

Calgary, Alberta, Canada – May 12, 2025 – TheNewswire - VoyageurPharmaceuticals Ltd. ( TSX.V:VM ) ( OTC Pink:VYYRF )(" Voyageur " or the " Company ") a radiology contrast mediacompany focused on vertical integration and secure supply chains, is pleased to announce the appointment of EthanMohan as Executive Vice President of Voyageur, subject to regulatoryapproval. Mr. Mohan's appointment is a promotion from his previousposition of Sales Manager of Voyageur and marks another strategicadvancement in the Company’s leadership team as it continues to movetowards the establishment of a sales presence.

Mr. Mohan has been a pivotal force behind forgingVoyageur’s sales strategies and strategic partnerships that have setthe stage for the Company’s market presence. Since joining Voyageur,Mr. Mohan has consistently demonstrated exceptional leadership,strategic foresight, and operational expertise, along with anunwavering commitment to advancing the Company’s vision of becominga global leader in the radiographic contrast agent market.

As Executive Vice President, Mr. Mohan will take on anexpanded role overseeing corporate strategy, business development, andinternational market expansion initiatives, while continuing tochampion Voyageur’s mission of delivering high-quality, sustainablebarium and iodine-based products to the global healthcaremarket.

“Ethan’s promotion marks an important milestone forVoyageur as we enter a transformative phase in our growth,” saidBrent Willis, CEO of Voyageur. “Ethan brings arare combination of scientific expertise and entrepreneurial acumenthat we expect will directly lead to the development of commercialsuccess for Voyageur. His leadership has positioned the Company to bein a position to capitalize on emerging global opportunities. As wemove forward with the development of Frances Creek, navigate FDAregulatory pathways, and scale our international footprint, Ethan’sstrategic insight and executional drive will be critical to propellingVoyageur into its next phase of expansion.”

Mr. Mohan added: “It is a privilege to step into therole of Executive Vice President at such a pivotal time inVoyageur’s evolution. As global demand for contrast mediaaccelerates, expected to reach $12.6 billion by 2032 ( https://www.grandviewresearch.com/industry-analysis/contrast-media-contrast-agents-market ), management of Voyageur believes it stands alone as theonly contrast media company with fully integrated, scalableresource-to-ready solutions capable of directly mitigating this globalsupply crisis.

Voyageur believes its steadfast commitment to thedevelopment of barium and iodine-based contrast agents will positionit to lead the market with a portfolio that is not only sustainableand cost-efficient, but purpose-built to elevate standards of careworldwide. By delivering high-quality, affordable contrast media,Voyageur aims to ease the burden on healthcare systems and enhancepatient outcomes globally. I am proud to be part of an organizationthat I believe is not just responding to market needs, but reshapingthe future of diagnostic imaging through innovation, execution, andpurpose-driven growth. We extend our sinceregratitude to our strategic partners and shareholders for theirresolute commitment as we continue to strive to achieve significant milestones in ourcommercial development.”

The Company congratulates Mr. Mohan on thiswell-deserved promotion and looks forward to his continuedcontributions as a member of the senior executive team.

About Voyageur PharmaceuticalsLtd.

Voyageur, a Canadian public company trading under thesymbol VM on the Exchange, is in development of barium and iodineActive Pharmaceutical Ingredients (API) that offer high-performanceand cost-effective imaging contrast agents. With a strategic focus onvertically integrating the barium and iodine contrast markets,Voyageur aims to become a key player by producing its own barium andiodine. In addition, Voyageur is pursuing the development of new endofullerene drugs.

Voyageur's business plan is set to generate cash flowby partnering with established third-party GMP pharmaceuticalmanufacturers in Canada thereby ensuring the validation of itsproducts by regulatory agencies worldwide. As Voyageur solidifies itspresence in the market, it plans to transition into a high-margindomestic manufacturer of radiology drugs.

Voyageur is committed to sustainability andenvironmental stewardship. Voyageur envisions a future where reducingcarbon emissions is the norm, and to achieve this, it intends to buildstate-of-the-art carbon-capture infrastructure utilising the RainCage EDEN TM system . Byinvesting in carbon capture energy sources and sustainablemanufacturing practices, Voyageur aims to generate revenue from carboncaptured “advanced carbon production”. Voyageur believes itsunwavering commitment to the environment sets it apart as a pioneer inthe industry.

At the core of its operations, Voyageur owns a 100%interest in the Frances Creek barium sulphate (barite) project.Currently, the worlds pharmaceutical barium sulphate is almostentirely synthetically produced resulting in a less effective imagingquality product. Voyageur’s Frances Creek resource boasts a rare andexceptional grade mineral suitable for the pharmaceutical marketplacethat Voyageur believes will replace the current synthetic productswith higher quality imaging products.

Voyageur's ambitious vision is to become the firstvertically integrated company in the radiology contrast media drugmarket. By controlling all primary input costs, from the sourcing ofraw materials to final production, Voyageur believes it can ensurequality and cost efficiency. With its approach, it embodies the mottoof "From the Earth to the Bottle," highlighting Voyageur'scommitment to responsible sourcing and manufacturing practices.

For Further Information:

Neither the TSX Venture Exchange nor its Regulation ServicesProvider (as that term is defined in the policies of the TSX VentureExchange) accepts responsibility for the adequacy or accuracy of thisnews release.

Cautionary Statement Regarding “Forward-Looking”Information

Thisnews release may contain certain forward-looking information andstatements, including without limitation, statements pertaining to:regulatory approval of Ethan Mohan's appointment as Executive VicePresident of the Corporation and Voyageur's business plans. Allstatements included herein,other than statements of historical fact, are forward-lookinginformation and such information involves various risks anduncertainties. There can be no assurance that such information willprove to be accurate, and actual results and future events coulddiffer materially from those anticipated in such information. Adescription of assumptions used to develop such forward-lookinginformation and a description of risk factors that may cause actualresults to differ materially from forward-looking information can befound in the Company's disclosure documents on the SEDAR+ website atwww.sedarplus.ca. Voyageur does not undertake to update anyforward-looking information except in accordance with applicablesecurities laws.

Copyright (c) 2025 TheNewswire - All rights reserved.